deltatrials

Gastroesophageal junction adenocarcinoma Trials in Madrid, Spain

Conditions / Gastroesophageal junction adenocarcinoma / Madrid, Spain

Clinical trials for Gastroesophageal junction adenocarcinoma investigate a range of treatment strategies and patient populations.

19 total trials for this combination

Showing top 10 of 19 trials

Trials

NCT ID Title Status Phase
NCT04772989 A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies COMPLETED PHASE1
NCT06324357 Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread RECRUITING
NCT06324357 Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread RECRUITING
NCT06324357 Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread RECRUITING
NCT06324357 Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread RECRUITING
NCT03170960 Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors ACTIVE_NOT_RECRUITING PHASE1
NCT06324357 Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread RECRUITING
NCT06324357 Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread RECRUITING
NCT03175224 APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors RECRUITING PHASE2
NCT06324357 Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread RECRUITING

Related Pages